Juvisync Approved for Type 2 Diabetics With High Cholesterol

Previously approved meds combined in one tablet

FRIDAY, Oct. 7 (HealthDay News) -- Juvisync (sitagliptin and simvastatin) has been approved by the U.S. Food and Drug Administration for people with type 2 diabetes who also have high cholesterol.

The FDA noted that recent studies have suggested that statins may prompt a rise in blood sugar levels among people with type 2 diabetes. But "this risk appears very small and is outweighed by the benefits of statins for reducing heart disease in diabetes," the agency said, noting it would require Juvisync's label to alert doctors to this possibility.

The FDA said it also would require Juvisync's manufacturer, the Irish drugmaker MSD International, to conduct post-approval studies that compare sitagliptin alone with the combination drug in lowering blood glucose levels.

The most common side effects of Juvisync are upper respiratory infection, congestion, sore throat, headache, muscle and stomach pain, constipation and nausea, the agency said.

More information

The American Diabetes Association has more about people with diabetes and high cholesterol.

Copyright © 2011 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

Dogs as Pets, Visitors, Therapists and Assistants
Home Healthcare Nurse, November/December 2014
Free access will expire on January 5, 2015.


Tracheostomy Care
Nursing2014 Critical Care, November 2014
Free access will expire on December 22, 2014.


Effective management of ARDS
The Nurse Practitioner, 13December 2014
Free access will expire on December 22, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events